focus -WSS

focus

author：Wikipedia 2025-09-27 10:05:26 - browse：98746

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

The benefits and risks of Eli Lilly’s treatment for Alzheimer’s disease were confirmed in detailed scientific disclosures Monday, paving the way for its full approval but leaving physicians with lingering questions about the medicine’s impact on patients as a new era in Alzheimer’s therapy unfolds.

The drug, called donanemab, showed a 35% slowing of Alzheimer’s disease progression relative to placebo in a clinical trial that enrolled 1,700 patients with early-stage disease. Numerically, that’s a modest, 3.3-point improvement on a 144-point survey, called the Integrated Alzheimer’s Disease Rating Scale, or iADRS, that combines measures of cognition and function, such as driving, managing finances, or carrying on conversations.

There was a similar benefit when donanemab’s efficacy was assessed using a more common measure of cognition called the Clinical Dementia Rating-Sum of Boxes, or CDR-SB. On that scale, the Lilly drug showed a 36% slowing of cognitive decline relative to placebo, or 0.68 points on an 18-point scale.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： FDA reorg will put new emphasis on investigations, sources say

leisure time

WSS

CDC: Cases of alpha

Hospitals, health systems can help patients avoid medical debt

‘We were in the air.’ Mississippi family recounts surviving tornado that tore mobile home apart

The Jan. 6 committee previously recommended Trump be criminally charged. Here's why

How state and local governments are sidelining science

'Hero' Louisville officer shot in head at mass shooting discharged over 3 months later

knowledge

focus

hotspot

Guidelines to prevent youth baseball injuries need more muscle

What is STAT's opinion section for?

Apple is now the first public company to be valued at $3 trillion

UnitedHealth sued over use of algorithm in Medicare Advantage plans

Malaria cases in Florida and Texas: Here’s what you need to know

First transplant of an entire human eye performed

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Trump lawyers meet with special counsel in Jan. 6 case as potential indictment looms

Apple is now the first public company to be valued at $3 trillion

Trump allegedly attempted to have surveillance video deleted: Special Counsel

entertainment

Will biotech layoffs continue through 2023?

Will biotech layoffs continue through 2023?

Type 2 diabetes prevention programs work at large scale: study

Marc Tessier

Readout Newsletter: Zepbound, Valneva's vaccine, and more

Study suggests Covid rebound is far more common with Paxlovid than without

focus

explore

leisure time

leisure time